LIFE SCIENCE TOOLS MARKET ANALYSIS

Life Science Tools Market, By Product (Consumables, Instruments, Services), By Technology (Genomics, Proteomics, Cell Biology, Stem Cell Research, Immunology), By Application (Drug Discovery and Development, Clinical Diagnostics, Genomic and Proteomic Research, Cell Biology Research, Others), By End User (Academic and Research Institutions, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Laboratories, Contract Research Organizations, Government and Regulatory Agencies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024
Code : CMI5357
Pages :190
Formats :
Excel and PDF
Industry : Medical Devices

Key Developments

In August 2023, Bio-Techne, a global life sciences company that provides innovative tools and bioactive reagents for the research and clinical diagnostic communities, collaborated with Akoya Biosciences, a biotechnology company, to co-develop an automated RNAscope workflow for use with the PhenoCycler-Fusion System.
In February 2023, BD (Becton, Dickinson and Company), one of the leading global medical technology companies, announced the launch of BD Rhapsody HT Xpress System, a new instrument for single-cell multiomics analysis. The system ensures no sample loss and gives scientists the flexibility to analyze multiple samples and different cell sizes and types, such as stem cells or cancer cells, at the same time, to obtain more insights in less time.
In January 2023, Illumina, Inc., announced that it has entered into a definitive co-development agreement with SomaLogic, a protein biomarker discovery and clinical diagnostics company, to bring the SomaScan Proteomics Assay onto Illumina, Inc. current and future high throughput Next-generation Sequencing (NGS) platforms.
In January 2023, Takara Bio, a pharmaceutical company, announced a collaboration with BioExcel Diagnostics, a laboratory specialized in molecular diagnostics and clinical genomics, to develop and validate a new high-throughput and comprehensive method for detecting syndromic-based infectious diseases. The method employs real-time polymerase chain reaction (PCR) automation technology and reagents from Takara Bio to detect viruses, bacteria, fungi, and antimicrobial resistance genes specific to the contributing pathogen.
In September 2022, Hoffmann-La Roche Ltd. launched the Digital LightCycler System (DLS), a digital polymerase chain reaction (PCR) system that is designed to aid in diagnostics for cancer, genetic disease, and infection. It detects the disease accurately and evaluates trace amounts of specific DNA and RNA targets that are not typically detectable by conventional PCR methods.